Bruker (NASDAQ:BRKR) returned to organic revenue growth in the second quarter, posted stronger bookings across its Scientific Instruments business, and maintained its earnings outlook while adjusting guidance for currency and tax changes.
Key Investor Takeaways
- Bruker (NASDAQ:BRKR) returned to organic revenue growth, with second-quarter revenue increasing 5.2% to $838.5 million.
- Scientific Instruments bookings rose 10% organically, with a book-to-bill ratio above 1.0x, pointing to continued order momentum.
- Non-GAAP EPS increased to $0.49 as operating margins improved despite a GAAP loss driven by a non-cash goodwill impairment charge.
- Management updated its 2026 outlook for currency and tax impacts while maintaining expectations for double-digit non-GAAP EPS growth.
- Strong demand in semiconductor tools, biopharma, and energy research helped offset continued softness in U.S. academic research spending.
Why (NASDAQ:BRKR) Stock Is in Focus
Bruker (NASDAQ:BRKR) reported second-quarter 2026 revenue of $838.5 million, up 5.2% year over year, with organic growth of 2.8%, or 3.4% excluding tariff refunds.
The company’s Bruker Scientific Instruments (BSI) segment generated 10% organic bookings growth during the quarter and achieved a book-to-bill ratio above 1.0x, while BSI revenue increased 4.7% to $767.3 million. The Bruker Energy & Supercon Technologies (BEST) segment delivered even faster revenue growth, rising 11.9% to $74.2 million.
Profitability improved on an adjusted basis despite a reported GAAP loss. Bruker posted a GAAP operating loss of $65.3 million and a GAAP diluted loss per share of $0.41, primarily reflecting $134.9 million in non-cash goodwill impairment charges. Excluding those and other adjustments, non-GAAP operating income increased to $118.5 million, operating margin expanded to 14.1%, and non-GAAP diluted EPS rose to $0.49 from $0.32 a year earlier.
Management also updated its fiscal 2026 guidance to reflect changes in currency and tax assumptions. Bruker now expects full-year revenue between $3.54 billion and $3.57 billion, representing 3% to 4% reported growth with 1% to 2% organic growth, while maintaining its non-GAAP EPS outlook of $2.10 to $2.15.
Why This Matters for Investors
The return to organic revenue growth and double-digit bookings growth in the Scientific Instruments business may indicate improving demand across several of Bruker’s core end markets.
Strong orders in semiconductor metrology, biopharma, and energy research suggest the company continues to benefit from investment in advanced research tools and technologies tied to AI-related semiconductor development. At the same time, management noted that U.S. academic demand remained soft, highlighting that the recovery is not yet broad across every customer segment.
The significant GAAP loss was driven by a non-cash goodwill impairment rather than operating performance, making margin expansion and higher adjusted earnings important metrics for investors evaluating the underlying business. The decision to maintain the company’s earnings outlook while only adjusting guidance for currency and tax changes may also support confidence in its operating expectations for the remainder of 2026.
What to Watch Next
Investors will be watching whether Bruker can sustain the improvement in Scientific Instruments bookings and convert that demand into stronger organic revenue growth over the coming quarters.
Key areas to monitor include recovery in U.S. academic research spending, continued demand from semiconductor and biopharma customers, execution on margin expansion initiatives, and progress toward the company’s full-year targets of $3.54 billion to $3.57 billion in revenue and non-GAAP EPS of $2.10 to $2.15.
Bruker Corporation stock price
